Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 17, 2019 16:05 ET | Source: Paratek Pharmaceuticals

Paratek Withdraws European Marketing Authorization Application for Oral and Intravenous NUZYRA in Skin Infections and Pneumonia

Application approvable by European Medicine Agency (EMA) for skin infections based on two Phase 3 studiesEMA requesting second study in CABP to meet regulatory standards of two Phase 3 studiesCompany...
October 01, 2019 16:30 ET | Source: Paratek Pharmaceuticals

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

BOSTON, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
September 25, 2019 08:00 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) Development Program at IDWeek 2019

BOSTON, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
September 09, 2019 08:00 ET | Source: Paratek Pharmaceuticals

Paratek Mourns Passing of Co-founder Dr. Stuart Levy

BOSTON, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) mourns the loss of Stuart Levy, M.D., who passed way last week. Dr. Levy co-founded the company more than two...
September 04, 2019 08:00 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference

BOSTON, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
September 03, 2019 16:05 ET | Source: Paratek Pharmaceuticals

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

BOSTON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
August 30, 2019 08:00 ET | Source: Paratek Pharmaceuticals

The Lancet Infectious Diseases Publishes Results from Paratek’s Phase 3 Oral only Dosing Study of NUZYRA® (omadacycline) for Skin Infections

BOSTON, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
August 26, 2019 16:05 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals to Present at Robert W. Baird’s 2019 Global Healthcare Conference

BOSTON, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
August 06, 2019 16:05 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals Generates Net Revenues of $2.0 Million in the Second Quarter of 2019

-- NUZYRA® (omadacycline) Net Sales increased 26% to $1.7 Million in the Second Quarter of 2019 -- -- Over 50% of Commercial Lives in U.S. now have Access to NUZYRA -- --...
August 01, 2019 16:05 ET | Source: Paratek Pharmaceuticals

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

BOSTON, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...